| Mon, Nov 9, 2009 | | • | Successful Pharmaceutical Company Mergers: Abbott Labs Is Leader
Wall Street Transcript (Mon 2:31pm)
| | • | A Bear in the Bullpen: 3 Power Ratings Stocks Ready to Drop
TradingMarkets.com (Mon 9:41am)
| | Sat, Nov 7, 2009 | | • | Elan, Biogen change Tysabri label due to PML risk
at Reuters (Sat, Nov 7)
| | Tue, Nov 3, 2009 | | • | Nice Quarter, Teva. What Will You Buy Next?
at Motley Fool (Tue, Nov 3)
| | • | UPDATE - J&J slashing workforce, cites cost of drug research
at Reuters (Tue, Nov 3)
| | • | Johnson & Johnson to cut up to 8,200 jobs
at MarketWatch (Tue, Nov 3)
| | Fri, Oct 30, 2009 | | • | Healthcare Earnings Are Coming Into Focus
at Investopedia (Fri, Oct 30)
| | Thu, Oct 29, 2009 | | • | Elan Corporation Plc Announces Expiration of Tender Offer for 7¾% Senior Fixed Rate Notes Due 2011
Business Wire (Thu, Oct 29)
| | • | 3 Stocks in a Tailspin
at Motley Fool (Thu, Oct 29)
| | • | UPDATE - EU agency reports 24th case of Tysabri infection
at Reuters (Thu, Oct 29)
| | • | 5-Star Stocks Poised to Pop: MEMC
at Motley Fool (Thu, Oct 29)
| | • | More PML Troubles for Biogen, Elan MS Drug: Biobuzz
at TheStreet.com (Thu, Oct 29)
| | • | Elan downgraded by UBS
Briefing.com (Thu, Oct 29)
| | Wed, Oct 28, 2009 | | • | FDA Approval for GlaxoSmithKline
Zacks.com (Wed, Oct 28)
| | Tue, Oct 27, 2009 | | • | Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's Disease
Business Wire (Tue, Oct 27)
| | • | Targeting Tysabri
at Forbes.com (Tue, Oct 27)
| | • | Trading Outlook for Elan Corp. Plc. Issued by InvestorSoup.com
GlobeNewswire (Tue, Oct 27)
| | Mon, Oct 26, 2009 | | • | For Tysabri, 23 Is 10 Too Many
at Motley Fool (Mon, Oct 26)
| | • | 5 Superball Stocks
at Motley Fool (Mon, Oct 26)
| | • | J&J CEO's Lower-Risk Alternative to Acquisitions
at The Wall Street Journal Online (Mon, Oct 26)
|
Add ELN News to My Yahoo!:
 
| |
|
2.03% Nasdaq 0.00%
Headlines
